PLCG1 mutations in cutaneous T-cell lymphomas

Blood

Volumn 123, Issue 13, 2014, Pages 2034-2043

  Vaqué, José P ^a   Gómez López, Gonzalo ^b   Monsálvez, Verónica ^c   Varela, Ignacio ^d   Martínez, Nerea ^a   Pérez, Cristina ^a   Domínguez, Orlando ^b   Graña, Osvaldo ^b   Rodríguez Peralto, José L ^c   Rodríguez Pinilla, Socorro M ^e   González Vela, Carmen ^a   Rubio Camarillo, Miriam ^b   Martín Sánchez, Esperanza ^a,b   Pisano, David G ^b   Papadavid, Evangelia ^f   Papadaki, Theodora ^g   Requena, Luis ^e   García Marco, José A ^h   Méndez, Miriam ^h   Provencio, Mariano ^h   Hospital, Mercedes ^h   Suárez Massa, Dolores ^h   Postigo, Concepción ^c   San Segundo, David ^a   López Hoyos, Marcos ^a   Ortiz Romero, Pablo L ^c   Piris, Miguel A ^a   Sánchez Beato, Margarita ^h   more..

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d University of Cantabria   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g EVANGELISMOS HOSPITAL   (Greece)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE C GAMMA1; TRANSCRIPTION FACTOR NFAT;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ENZYME ACTIVE SITE; FRAMESHIFT MUTATION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MISSENSE MUTATION; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TISSUE SECTION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA, T-CELL; MALE; MICE; MUTATION; NIH 3T3 CELLS; PHOSPHOLIPASE C GAMMA; SKIN NEOPLASMS;

EID: 84897520067     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504308     Document Type: Article

References (49)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785. (Pubitemid 40656118)
2. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105(4):1640-1647. (Pubitemid 40223685)
3. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064-5073.
4. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
5. Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(16):4812-4821. (Pubitemid 44338565)
6. Cirée A, Michel L, Camilleri-Bröet S, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer. 2004;112(1):113-120. (Pubitemid 39249498)
7. Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia. 2012;26(3):424-432.
8. Kasprzycka M, Zhang Q, Witkiewicz A, et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4-T lymphocytes. J Immunol. 2008;181(4):2506-2512.
9. Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 2012;119(15):3534-3538.
10. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 2010;467(7318):967-971.
11. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol. 2011;131(6):1331-1338.
12. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709-718. (Pubitemid 36629749)
13. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155(2):150-166.
14. Lamprecht B, Kreher S, Möbs M, et al. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. Br J Dermatol. 2012;167(2):240-246.
15. Kiessling MK, Oberholzer PA, Mondal C, et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. 2011;117(8):2433-2440.
16. Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol. 2002;147(3):464-475. (Pubitemid 35015279)
17. Caprini E, Cristofoletti C, Arcelli D, et al. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. Cancer Res. 2009;69(21):8438-8446.
18. Salgado R, Servitje O, Gallardo F, et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol. 2010;130(4):1126-1135.
19. Lin WM, Lewis JM, Filler RB, et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J Invest Dermatol. 2012;132(1):188-197.
20. Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res. 2008;68(8):2689-2698. (Pubitemid 351556266)
21. Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sézary syndrome. Genes Chromosomes Cancer. 2003;36(3):250-260. (Pubitemid 36158198)
22. Iżykowska K, Przybylski GK. Genetic alterations in Sezary syndrome. Leuk Lymphoma. 2011;52(5):745-753.
23. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
24. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
25. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
26. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
27. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
28. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
29. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
30. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
31. Papaemmanuil E, Cazzola M, Boultwood J, et al Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384-1395.
32. Jaffe ES, Harris NL, Stein H, eds. JWV. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
33. Olsen EA,Whittaker S, Kim YH, et al International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607.
34. Rubio-Camarillo M, Gómez-López G, Fernández JM, Valencia A, Pisano DG. RUbioSeq: a suite of parallelized pipelines to automate exome variation and bisulfite-seq analyses. Bioinformatics. 2013;29(13):1687- 1689.
35. Doménech E, Gómez-López G, Gzlez-Peña D, et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PLoS ONE. 2012;7(6):e38158.
36. Zhong XP, Shin J, Gorentla BK, et al. Receptor signaling in immune cell development and function. Immunol Res. 2011;49(1-3):109-123.
37. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472-484. (Pubitemid 40835035)
38. Park JB, Lee CS, Jang JH, et al. Phospholipase signalling networks in cancer. Nat Rev Cancer. 2012;12(11):782-792.
39. Sundrud MS, Nolan MA. Synergistic and combinatorial control of T cell activation and differentiation by transcription factors. Curr Opin Immunol. 2010;22(3):286-292.
40. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther. 2011;12(12):1019-1022.
41. Wilde JI, Watson SP. Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal. 2001;13(10):691-701. (Pubitemid 32800818)
42. Rallis E, Economidi A, Verros C, Papadakis P. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol. 2006;5(9):906-907.
43. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405-1410. (Pubitemid 36005628)
44. Wu CS, Wang ST, Liao CY, Wu MT. Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. Kaohsiung J Med Sci. 2008;24(11):577-590.
45. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol. 2009;129(5):1115-1119.
46. Chang DK, Sui J, Geng S, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012;11(11):2451-2461.
47. Tracey L, Villuendas R, Ortiz P, et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol. 2002;161(5):1825-1837. (Pubitemid 35265540)
48. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785-3794.
49. Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7):1288-1295. (Pubitemid 39023140)